Future innovations in anti‐platelet therapies
Open Access
- 1 July 2008
- journal article
- review article
- Published by Wiley in British Journal of Pharmacology
- Vol. 154 (5) , 918-939
- https://doi.org/10.1038/bjp.2008.151
Abstract
Platelets have long been recognized to be of central importance in haemostasis, but their participation in pathological conditions such as thrombosis, atherosclerosis and inflammation is now also well established. The platelet has therefore become a key target in therapies to combat cardiovascular disease. Anti‐platelet therapies are used widely, but current approaches lack efficacy in a proportion of patients, and are associated with side effects including problem bleeding. In the last decade, substantial progress has been made in understanding the regulation of platelet function, including the characterization of new ligands, platelet‐specific receptors and cell signalling pathways. It is anticipated this progress will impact positively on the future innovations towards more effective and safer anti‐platelet agents. In this review, the mechanisms of platelet regulation and current anti‐platelet therapies are introduced, and strong, and some more speculative, potential candidate target molecules for future anti‐platelet drug development are discussed. British Journal of Pharmacology (2008) 154, 918–939; doi:10.1038/bjp.2008.151; published online 21 April 2008Keywords
This publication has 292 references indexed in Scilit:
- The role of von Willebrand factor in thrombus formationPublished by Elsevier ,2007
- Platelet CD36 links hyperlipidemia, oxidant stress and a prothrombotic phenotypeNature Medicine, 2007
- A Comprehensive Proteomics and Genomics Analysis Reveals Novel Transmembrane Proteins in Human Platelets and Mouse Megakaryocytes Including G6b-B, a Novel Immunoreceptor Tyrosine-based Inhibitory Motif ProteinMolecular & Cellular Proteomics, 2007
- Regulated surface expression and shedding support a dual role for semaphorin 4D in platelet responses to vascular injuryProceedings of the National Academy of Sciences, 2007
- The role of platelet adhesion receptor GPIbα far exceeds that of its main ligand, von Willebrand factor, in arterial thrombosisProceedings of the National Academy of Sciences, 2006
- Disulfide isomerization switches tissue factor from coagulation to cell signalingProceedings of the National Academy of Sciences, 2006
- Structure of the Semaphorin-3A Receptor Binding ModuleNeuron, 2003
- Human platelets contain p110δ phosphoinositide 3-kinaseBiochemical and Biophysical Research Communications, 2002
- Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patientsBMJ, 2002
- Receptors and signalling mechanisms in the procoagulant response of plateletsPlatelets, 2000